Investment Management Software Enfusion Prices US$318.75 Million IPO

Accounts payable automation software Enfusion, Inc. (NYSE: ENFN) started publicly trading on the New York Stock Exchange today. The firm’s initial public offering is looking to raise US$318.75 million.

The offering will be conducted through the issuance of 18.75 million Class A common shares selling at US$17.00 per share. Out of this, around 3.43 million shares will be sold by the company’s existing stockholders while the remaining 15.32 million shares will be offered by the company itself.

The company granted the underwriters a 30-day over-allotment option to purchase additional 2.81 million common shares at the same IPO price. Morgan Stanley & Co. and Goldman Sachs & Co. are all acting as joint lead bookrunners for the said offering.

The firm also relayed that it intends to use the offering proceeds to purchase equity interests in its operating subsidiary Enfusion Ltd. which in turn will use the funds to repay indebtedness and pay IPO-related expenses.

The offering is expected to close on October 25, 2021, subject to customary closing conditions.

Enfusion is a cloud-based investment management software platform aimed at streamlining the investment process by tying the front, middle, and back-office functions. The firm is currently present in nine global offices partnering with 600+ investment managers.


Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Agnico Q1 Earnings Results Overshadowed By A Sinking Gold Price

Why More People Are Starting to Feel Broke | Darrell Thomas – VRIC Media

Newmont Q1 Earnings: A Billion In Free Cash Flow… A Month!

Recommended

Selkirk Copper Strikes New Lens Beneath Old Pit, Launches 50,000 Metre Phase 2 Program

Silver47 Pulls High-Grade Gold and Silver Assays from Nevada Vein Network At Kennedy

Related News

Chinese Biotech Firm LianBio Prices US$325 Million Nasdaq IPO

Biotech company LianBio (Nasdaq: LIAN) started trading on the Nasdaq Global Market today. The Shanghai-based...

Monday, November 1, 2021, 02:07:00 PM

Asset Manager TPG Prices US$1 Billion IPO

Private equity firm TPG Inc. (Nasdaq: TPG) began trading on the Nasdaq Global Select Market...

Thursday, January 13, 2022, 02:22:00 PM

Oncology Firm TransCode Therapeutics Looks To Raise US$25 Million In IPO

Oncology company TransCode Therapeutics, Inc. is set to begin publicly trading its equityon the Nasdaq...

Friday, July 9, 2021, 09:53:00 AM

PropTech SPAC Jaguar Global Growth Prices US$200 Million IPO

Special purpose acquisition company Jaguar Global Growth Corporation I (Nasdaq: JGGCU) started trading on the...

Monday, February 14, 2022, 02:12:00 PM

Semrush: The IPO Deep Dive

Semrush (NYSE: SEMR) is an online platform that offers a suite of tools to companies,...

Thursday, March 25, 2021, 12:31:00 PM